MaxCyte (MXCT) Stifel 2024 Healthcare Conference summary

Market overview and technology trends

• Cell and gene therapy is rapidly evolving, with a shift from viral to non-viral and ex vivo approaches due to increasing complexity and the need for multiple cell edits.

• Non-viral, ex vivo engineering now represents a growing share of the market, with electroporation platforms enabling more complex therapies.

• The number of cell and gene therapy programs in research and clinical stages is expanding, with over 2,100 programs and 1,200 in the clinic.

• The industry is moving beyond oncology into rare and autoimmune diseases, broadening the addressable market.

• Recent regulatory developments, such as FDA flexibility in trial phases, are accelerating clinical progress for cell and gene therapies.

Financial performance and outlook

• Cell therapy revenues increased by 40% year-over-year, reflecting strong activity and improved funding in 2024.

• The funding environment rebounded in 2024, especially for companies with programs near the clinic, supporting demand.

• Management expects continued healthy performance in Q4 2024 and is optimistic about growth in 2025, contingent on market recovery.

• Instrument sales remain the majority, but leasing activity is increasing, particularly among strategic partners.

• Gross margins are expected to remain in the mid-80s% range, with potential to approach previous highs as utilization increases.

Strategic platform licenses (SPLs) and revenue drivers

• SPLs provide recurring revenue through license fees, system usage, and royalties, with 29 partners currently in the clinic.

• Six new SPLs were signed in 2024, above the typical annual range, setting up for future growth.

• The aggregate value of pre-commercial SPL milestones has grown to around $2 billion, indicating significant long-term potential.

• Revenue from SPLs is expected to become less lumpy and more predictable as more programs mature and reach commercial stages.

• Milestone and royalty revenue is anticipated to ramp up in 2026–2027 as additional SPL products reach approval.